OrbiMed Advisors PHGE Position
ExitedOrbiMed Advisors exited their position in BiomX Inc. (PHGE) in Q2 2025, after holding the stock for 10 quarters.
The position was first reported in Q1 2023 and has been tracked across 10 quarterly 13F filings.
1 other tracked fund also holds PHGE.
About BiomX Inc.
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Full company profile →Short Interest
1.3%
1.0 days to cover
OrbiMed Advisors PHGE Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q2 2025 | Exited | 0 | -1,787,767 | $0 |
| Q1 2025 | Held | 1,787,767 | — | $993K |
| Q4 2024 | Held | 1,787,767 | — | $1.3M |
| Q3 2024 | Decreased | 1,787,767 | -11,985,886 | $1.8M |
| Q2 2024 | Increased | 13,773,653 | +9,256,064 | $4.6M |
| Q1 2024 | Held | 4,517,589 | — | $2.0M |
| Q4 2023 | Decreased | 4,517,589 | -35,900 | $1.3M |
| Q3 2023 | Held | 4,553,489 | — | $1.6M |
| Q2 2023 | Increased | 4,553,489 | +1,392,000 | $1.6M |
| Q1 2023 | New | 3,161,489 | +3,161,489 | $964K |
Frequently Asked Questions
Does OrbiMed Advisors own PHGE?
No. OrbiMed Advisors exited their position in BiomX Inc. (PHGE) in Q2 2025. They previously held the stock for 10 quarters.
How many hedge funds own PHGE?
1 specialist biotech hedge fund currently holds PHGE, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy PHGE?
OrbiMed Advisors's position in PHGE was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's PHGE position increasing or decreasing?
OrbiMed Advisors completely exited their PHGE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PHGECompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →